Cancer
Patient experience: Living with multiple myeloma
February 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, feature, mutiple myeloma, patient experience, pharma
Pharmafocus talks to John Ellwood about the challenges of being diagnosed with multiple myeloma and how having a strong support …
Ovarian cancer risk may be inherited from the father, research indicates
February 16, 2018Medical Communications, Research and Development Cancer, Roswell Park Comprehensive Cancer Centre, ovarian cancer
Researchers at the Roswell Park Comprehensive Cancer Centre in New York have published findings indicating that ovarian cancer risk may …
Roche boosts cancer efforts with $1.9 billion buyout of Flatiron Health
February 16, 2018Medical Communications, Sales and Marketing Cancer, Flatiron health, Roche, acquisition, oncology, pharma
Roche has announced it is to acquire privately held healthcare and technology firm Flatiron Health for $1.9 billion to leverage …
J&J’s apalutamide scores snap FDA approval in castration-resistant prostate cancer subgroup
February 15, 2018Sales and Marketing Cancer, Erleada, FDA, J&J, JJ, Johsnon & Johnson, apalutamide, pharma, prostate cancer
Johnson & Johnson has announced that its androgen receptor inhibitor apalutamide, now branded as Erleada, has received approval from the …
Cancer-targeting nanorobots successfully starve and shrink tumours, study shows
February 13, 2018Manufacturing and Production, Research and Development Arizona State university, Cancer, Chinese Academy of Sciences, National Center for Nanoscience and Technology, nanorobots, pharma
A team of researchers from Arizona State University (ASU), in partnership with the Chinese Academy of Sciences’ National Center for …
FDA expands J&J Zytiga combo’s indication to include castration-sensitive prostate cancer
February 9, 2018Medical Communications, Sales and Marketing Cancer, FDA, J&J, JJ, Janssen, Johnson & Johnson, Zytiga, pharma
Johnson & Johnson has announced that Zytiga (abiraterone acetate) in combination with prednisone has been awarded FDA approval in the …
Abbott teams up with Angle for metastatic breast cancer study
February 6, 2018Manufacturing and Production, Research and Development Abbott, Angle, Cancer, breast cancer, pharma
Abbott is set to join forces with liquid biopsy medtech firm Angle to collaborate on a study into metastatic breast …
UK breast cancer mortality falls 10% over five years, overtaken by prostate deaths for first time
February 5, 2018Research and Development, Sales and Marketing Cancer, Cancer Research UK, breast cancer, pharma, prostate cancer
Breast cancer deaths in the UK have fallen by 10% in the past five years, according to research released by …
AstraZeneca scores double approvals in Japan for asthma and ovarian cancer
January 19, 2018Medical Communications, Sales and Marketing AstraZeneca, Cancer, Fasenra, Japan, asthma, lynparza, ovarian cancer, pharma
AstraZeneca has unveiled a double dose of approvals awarded to its medicines in Japan: Fasenra (benralizumab) has been given authorisation …
Pfizer’s Xalkori sees rejection at the hands of NICE in lung cancer
January 19, 2018Medical Communications, Sales and Marketing Cancer, NCIE, NSCLC, Pfizer, UK, Xalkori, lung cancer, pharma
UK regulator NICE has announced its decision not to recommend Pfizer’s Xalkori (crizotinib) for use on the NHS in the …
Boehringer’s Gilotrif approved in US for lung cancer with non-resistant EGFRs
January 16, 2018Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, Cancer, FDA, Giltrif, NSCLC, lung cancer
Boehringer Ingelheim is celebrating the FDA’s decision to expand the indication of its lung cancer drug Gilotrif (afatinib) to include …
AZ and MSD’s Lynparza becomes first PARP inhibitor approved in US for metastatic breast cancer
January 15, 2018Sales and Marketing AstraZeneca, Cancer, FDA, MSD, breast cancer, lynparza, pharma
The FDA has announced that it has awarded marketing authorisation in the US to Lynparza (olaparib), a poly ADP-ribose polymerase …
FDA clears Amgen’s bone drug for multiple myeloma
January 8, 2018Sales and Marketing Amgen, Cancer, Xgeva, multiple myeloma, pharma
Amgen has announced that the FDA has approved the indication expansion of its drug Xgeva (denosumab) to include the treatment …
Higher mutational burdens in tumours linked to greater immunotherapy success, study finds
December 21, 2017Research and Development Cancer, Johns Hopkins Kimmel Cancer Center, checkpoint inhibitors, mutational burden, pharma
New research from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Cancer Institute for Cancer Immunotherapy has indicated that …
FDA grants breast cancer approval to Roche’s Perjeta/Herceptin combo therapy
December 21, 2017Sales and Marketing Cancer, FDA, Herceptin, Perjeta, Roche, breast cancer, pharma
Roche has announced that the FDA has granted approval to Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and a (Perjeta-based) …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
